## Prostate Cancer Quarterly Benchmarks Report Fiscal Year 2010 2nd Quarter Report

Jurisdiction/Program: ALL

Sponsor: CRF

			Period:	7/1-9/30	10/1-12/31	1/1-3/31	4/1-6/30	7/1/-6/30
			Run Date:	05/13/2010	05/13/2010			
Category	No.	Indicator	Standard	FY10 1Q	FY10 2Q	FY10 3Q	FY10 4Q	FY10 Total
Screening Priority Population	1	Percent of prostate cancer screenngs with both PSA and DRE	≥80%	82.9	98.9			
Case Management Among Program- eligible Clients	2	Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with a diagnosis status of 'Complete'	≥80%	100.0	83.3			
	3	Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with date of diagnosis within 90 days of screening among those with diagnosis status of 'Complete'	≥80%	50.0	60.0			
	4	Percent of prostate cancers diagnosed with treatment started	≥80%	No Data	100.0			
	5	Percent of prostate cancers with treatment started within 60 days of diagnosis among those who started treatment	≥80%	No Data	16.7			
	6	Percent of prostate cancers with stage information among clients diagnosed with cancer who had surgery	≥80%	0.0	0.0			
Notification	7	Percent of PSA results received by the program within 28 days of test	≥80%	89.9	94.4			
	8	Percent of men ever notified of screening* results by program	≥95%	100.0	99.1			
	9	Percent of men with abnormal findings/needs further evaluation to rule out cancer, were notifed of results, and were notified by program within 7 days of when screening^ results received by program	≥80%	76.9	36.0			

\*Screening means screened with Prostate Specific Antigen (PSA) and/or Digital Rectal Exam (DRE) \*Screening means screened with Prostate Specific Antigen (PSA) or PSA and Digital Rectal Exam (DRE)